IND-enabling epicardial biopharmaceutical in the diabetic heart
Ended Project Grant Awarded Last action
- Award ID
- R44HL140649
- Recipient
-
Regencor Inc. UEI JMCMLK8N5HR7
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $7,724,273
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Originally
- Funding
-
- $5,963,577.00 Federal
- $1,760,696.00 Non-federal
- Place of performance
- California, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $1,760,696 | $0 | |
| Amendment | $1,760,696 | $1,760,696 | |
| Amendment | $1,997,399 | $0 | |
| Original award | $444,786 | $0 |
Quick answers
Who received award R44HL140649?
R44HL140649 was awarded to Regencor Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on August 15, 2018.
How much is award R44HL140649 worth?
$7,724,273 has been obligated on R44HL140649: $5,963,577 in federal funding and $1,760,696 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award